New Tefferi paper text (4)
Posted: Mon Apr 19, 2021 5:10 pm
lenalidomide have also been reported in MDS-RS.21 By contrast, as was underlined in the current edition of AJH by Montalban-Bravo et al,2 as well as noted in previous publications,15 therapeutic success with hypomethylating agents in MDS/MPN-RS-T has been less than stellar and not much better in MDS-RS.21 Regardless, current data argues for the value of ESAs as front-line treatment of choice for anemia associated with MDS/MPN-RS-T or MDS-RS and identify lenalidomide as a reasonable second-line treatment of choice, before resorting to luspatercept.22 Whether or not newer drugs, in-class or otherwise, that target specific regulators of erythropoiesis, including those that modulate hepcidin expression, would perform better remains to be seen